Your session is about to expire
← Back to Search
ABBV-383 for Multiple Myeloma
Study Summary
This trial will investigate the safety, effectiveness, and tolerability of ABBV-383 in adult participants with relapsed/refractory MM. Researchers want to measure adverse events and changes in symptoms of the disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You must have a disease that can be measured according to the study guidelines.I have never been treated with ABBV-383.I've had 3+ treatments including PI, IMiD, and anti-CD38 for my condition.I've had 2+ treatments for my condition, including specific targeted therapies.My multiple myeloma has worsened despite treatment.I can take care of myself but might not be able to do heavy physical work.I have received therapy targeting BCMA.
- Group 1: Arm B: ABBV-383 Dose Expansion
- Group 2: Arm A (Part 1): ABBV-383 Dose Escalation
- Group 3: Arm A (Part 2): ABBV-383 Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the ABBV-383 Dose Expansion received regulatory clearance?
"The ABBV-383 Dose Expansion trial has been assigned a safety score of 1. This is because, as it's only in the first clinical testing stage, there are limited data sets available to support its efficacy and safety."
What is the current extent of facilities conducting this trial?
"For this clinical trial, recruitment is taking place at Mt Sinai /ID# 251166 in New york City, Tulane University /ID# 251204 in New Orleans and Mayo Clinic Arizona /ID# 251405 located in Phoenix along with 6 other medical centres."
Is there still availability for individuals to join this experiment?
"According to records on clinicaltrials.gov, patient recruitment for this medical trial closed in December of 2022 - as such it is no longer seeking new participants. However, 811 other studies are presently looking for volunteers and patients."
Share this study with friends
Copy Link
Messenger